Swiss pharma at risk of US trade investigation, industry body says

The United States could open a trade investigation into Switzerland's pharmaceutical industry, echoing the probe launched last week against Germany. The prospect raises tariff and regulatory risk for Swiss drugmakers, but the article does not specify any immediate policy action or timeline. Market impact is likely limited to the affected healthcare names unless the investigation broadens.

Analysis

The United States could open a trade investigation into Switzerland's pharmaceutical industry, echoing the probe launched last week against Germany. The prospect raises tariff and regulatory risk for Swiss drugmakers, but the article does not specify any immediate policy action or timeline. Market impact is likely limited to the affected healthcare names unless the investigation broadens.